Produkt, der indeholder i det mindste en CDC25-phosphatase-inhibitor, i kombination med i det mindste et andet anti-cancer-middel

Produkt, der indeholder i det mindste en CDC25-phosphatase-inhibitor, i kombination med i det mindste et andet anti-cancer-middel

Composition comprises at least one Cdc25 phosphatase inhibitor (I) in combination with at least one other anticancer agent (II), for simultaneous, separate or successive use in the treatment of cancer. ACTIVITY : Cytostatic. In tests for inhibition of proliferation of HT-29 (human colon cancer) cell...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: PREVOST, GREGOIRE, BREZAK PANNETIER, MARIERISTINE
Format: Patent
Sprache:dan
Schlagworte:
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Composition comprises at least one Cdc25 phosphatase inhibitor (I) in combination with at least one other anticancer agent (II), for simultaneous, separate or successive use in the treatment of cancer. ACTIVITY : Cytostatic. In tests for inhibition of proliferation of HT-29 (human colon cancer) cells in vitro, the degree of cell survival after 6 days was 36% in presence of 1 MicroM 5-((2-(dimethylamino)-ethyl)-amino)-2-methyl-1,3-benzothiazole-4,7-dione (Ia) (as the hydrochloride), 44% in presence of 50 MicroM roscovitine (IIa) and 0% in presence of a combination of 1 MicroM (Ia) and 50 MicroM (IIa). MECHANISM OF ACTION : Cdc25 phosphatase inhibitor.